Mindset Pharma

Mindset Pharma is a drug discovery and development company focused on creating optimized, next-generation psychedelic medicines to treat neurological and psychiatric disorders. The company utilizes a proprietary drug discovery platform to design novel small molecules that aim to improve the safety, efficacy, and pharmacokinetics of first-generation psychedelic compounds like psilocybin and DMT. Mindset's lead candidate, MSP-1014, is a psilocybin analog being developed for major depressive disorder and is currently in Phase 1 clinical trials. In 2023, the company was acquired by Otsuka Pharmaceutical, integrating its innovative pipeline into Otsuka's broader central nervous system portfolio. The acquisition highlights Mindset's role as a pioneer in the medicinal chemistry of psychedelic substances.